Ontology highlight
ABSTRACT: Purpose
Exposure to the polyphenolic plant lignan secoisolariciresinol diglucoside (SDG) and its metabolite enterolactone (ENL) has been associated with reduced breast cancer progression, particularly for estrogen receptor alpha (ER?)-negative disease, and decreased preclinical mammary tumor growth. However, while preclinical studies have established that SDG and ENL affect measures of progression in models of triple-negative breast cancer (TNBC, a subset of ER?-negative disease), the molecular mechanisms underlying these effects remain unclear.Methods
C57BL/6 mice were fed a control diet (control, 10% kcal from fat) or control diet?+?SDG (SDG, 100 mg/kg diet) for 8 weeks, then orthotopically injected with syngeneic E0771 mammary tumor cells (a model of TNBC); tumor growth was monitored for 3 weeks. The role of reduced NF-?B signaling in SDG's anti-tumor effects was explored in vitro via treatment with the bioactive SDG metabolite ENL. In addition to the murine E0771 cells, the in vitro studies utilized MDA-MB-231 and MCF-7 cells, two human cell lines which model the triple-negative and luminal A breast cancer subtypes, respectively.Results
SDG supplementation in the mice significantly reduced tumor volume and expression of phospho-p65 and NF-?B target genes (P?ConclusionsSDG reduces tumor growth in the E0771 model of TNBC, likely via a mechanism involving inhibition of NF-?B activity. SDG could serve as a practical and effective adjuvant treatment to reduce recurrence, but greater understanding of its effects is needed to inform the development of more targeted recommendations for its use.
SUBMITTER: Bowers LW
PROVIDER: S-EPMC6394576 | biostudies-literature | 2019 Feb
REPOSITORIES: biostudies-literature
Bowers Laura W LW Lineberger Claire G CG Ford Nikki A NA Rossi Emily L EL Punjala Arunima A Camp Kristina K KK Kimler Bruce K BK Fabian Carol J CJ Hursting Stephen D SD
Breast cancer research and treatment 20181026 3
<h4>Purpose</h4>Exposure to the polyphenolic plant lignan secoisolariciresinol diglucoside (SDG) and its metabolite enterolactone (ENL) has been associated with reduced breast cancer progression, particularly for estrogen receptor alpha (ERα)-negative disease, and decreased preclinical mammary tumor growth. However, while preclinical studies have established that SDG and ENL affect measures of progression in models of triple-negative breast cancer (TNBC, a subset of ERα-negative disease), the mo ...[more]